When Should Biotech Founders Approach Pharma?
Founders often assume there is one ideal moment to approach pharma: after the data are complete. In reality, there are two different reasons to engage a strategic partner—learning and transacting—and the timing can be different for each.
Engage Early to Learn
Non-confidential conversations can help a founder understand how a potential partner thinks about the indication, competitive landscape, modality, evidence package, development stage, and internal priorities. Those conversations can shape the roadmap long before a formal partnering process.
Engage Later to Negotiate from Evidence
A formal licensing or acquisition discussion is stronger when the company can show a clear asset, credible IP, a defined indication, reproducible data, a development plan, and evidence aligned with the partner's risk threshold.
What Creates Strategic Interest?
Different companies have different thresholds, but the following factors commonly influence interest.
- Strategic fit with pipeline and therapeutic area
- Clear differentiation from current and emerging alternatives
- Protectable IP and manageable diligence issues
- Reproducible, decision-relevant data
- Defined development and regulatory path
- Commercial opportunity large enough to matter
- A realistic deal structure and development plan
Do Not Confuse a Meeting with Validation
Business-development teams meet many companies. Interest, a follow-up call, or a confidentiality agreement is useful signal but is not the same as a term sheet. Track what evidence the partner says it needs next and use that information to prioritize development.
Create Competitive Tension Carefully
A structured outreach process can improve learning and negotiating leverage, but founders should avoid overstating partner interest or launching a broad process before the asset is ready for diligence.
BYB Takeaway
Approach pharma early enough to learn what matters, but try to negotiate after you have created the evidence that improves your leverage.
Ask strategic partners what would need to be true for the program to become actionable internally.
